Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABT
ABT logo

ABT News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ABT News

Abbott Laboratories Q4 2025 Financial Results Analysis

1d agoYahoo Finance

Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments

13h agoCNBC

Abbott Laboratories Shares Rise 1.75% After Six-Day Decline

3d agoseekingalpha

Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie

4d agoFool

Analysis of Dividend Stock Investment Opportunities

4d agoFool

High Dividend Stocks Investors Should Focus On

4d agoFool

AbbVie and Realty Income's Stable Dividend Prospects

4d agoNASDAQ.COM

Abbott Laboratories Attracts Income Investors

May 03 2026Fool

ABT Events

04/29 12:30
FDA Announces Results of Infant Formula Contaminant Testing
The U.S. Food and Drug Administration announced results from the "largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market. While breast milk is widely considered the gold standard and optimal source of nutrition for infants whenever possible, millions of parents depend on formula." "We tested more infant formula than ever before, and the results are clear: most products meet a high safety standard-but even small exposures matter for newborns," said Health and Human Services Secretary Robert F. Kennedy, Jr. "We will hold manufacturers accountable, and give parents honest, transparent data they can trust. Protecting our children's health is nonnegotiable." Across the products tested, an overwhelming majority of samples had undetectable or very low levels of contaminants, affirming that the U.S. infant formula supply is safe. The FDA tested more than 300 infant formula samples representative of products sold at retail across the U.S.-generating more than 120,000 data points-for lead, mercury, cadmium, arsenic, pesticides, per- and polyfluoroalkyl substances, and phthalates. The samples, which included powders, ready-to-feed liquids, and concentrated liquids, were rigorously tested and analyzed in FDA laboratories. The FDA will continue to test infant formula as part of Operation Stork Speed and ongoing surveillance of foods, including testing infant formula products that have entered the U.S. market since this initial survey began and conducting additional compliance sampling. Publicly traded companies that make infant formula include Nestle (NSRGY), Danone (DANOY), and Abbott (ABT).
04/28 09:10
Abbott Receives FDA and CE Clearance for Ultreon 3.0 Software
Abbott received FDA clearance and CE Mark for its Ultreon 3.0 Software. Ultreon 3.0 is an AI powered imaging platform that uses optical coherence tomography to give doctors real-time planning guidance while they perform minimally invasive procedures to open blocked heart arteries known as percutaneous coronary intervention.

ABT Monitor News

Abbott Laboratories Faces Challenges Amid Legal Pressure and Market Conditions

May 08 2026

Abbott Reports Q1 2026 Growth Amid Acquisition Impact

Apr 21 2026

Abbott Reports Strong Q1 2026 Financial Results with Strategic Acquisition

Apr 16 2026

Abbott Ordered to Pay $53M for Infant Formula Lawsuit

Apr 10 2026

Abbott Reports Q4 2025 Earnings with Mixed Results

Jan 22 2026

ABT.N Hits 20-Day Low Amid Acquisition News

Nov 20 2025

ABT Earnings Analysis

Abbott Q1 2024 Earnings: Strong Results Despite Challenges- Intellectia AI™
1 years ago
Abbott Q1 2025: Strong Growth in Medical Devices- Intellectia AI™
1 years ago
Abbott's Resilient Growth in Healthcare - Intellectia AI™
1 years ago

People Also Watch